Lipoprotein composition in children and adolescents with type 1 diabetes mellitus

Journal of Pediatric Endocrinology and Metabolism

Volumn 18, Issue 3, 2005, Pages 257-264

  Bustos, A Paulino ^a   Radojkovic, Claudia ^a   Ulloa, Natalia ^a   Muñoz, Mirna ^a   Martínez, Alejandro ^a   Calvo, Carlos ^a   Asenjo, Sylvia ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Glycosylated lipoproteins; Lipoprotein distribution; Type 1 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CHILD; CHILE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN BLOOD LEVEL; MALE; MORBIDITY; MORTALITY; PREVALENCE; PROTEIN GLYCOSYLATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 15844374170     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2005.18.3.257     Document Type: Article

References (44)

1. Baynes J, Thorpe S. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000; 28: 1708-1716.
2. Bierman E. Atherogenesis in diabetes. Arterioscler Thromb 1992; 12: 647-656.
3. Vergès BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999; 3: 32-40.
4. Garg A. Management of dyslipidemia in IDDM patients. Diabetes Care 1994; 17: 224-234.
5. Annuzzi G, Iovine C, Mandarino B, Patti L, Di Marino L, Riccardi G, Rivellese AA. Effect of acute exogenous hyperinsulinaemia on very low density lipoprotein subfraction composition in normal subjects. Eur J Clin Invest 2001; 31: 118-124.
6. Pérez A, Wägner A, Carreras G, Gimenez G, Sanchez-Quesada JL, Rigla M, Gomez-Gerique JA, Pou JM, de Leiva A. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus. Arch Intern Med 2000; 160: 2756-2762.
7. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984; 25: 1017-1058.
8. Fruchart JC, Ailhaud G. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem 1992; 38: 793-797.
9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against heart disease. The Framingham study. Am J Med 1977; 62: 707-714.
10. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-β-migrating high density lipoprotein. Biochemistry 1988; 27: 25-29.
11. Glomset J. The plasma lecithin: cholesterol acyl transferase reaction. J Lipid Res 1968; 9: 155-167.
12. Tall A. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 29: 1593-1602.
13. Igau B, Lestavel S, Clavey V, Slomianny C, Drouin P, Bresson R, Fruchart JC, Duriez P, Fievet C. Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes. Atherosclerosis 1996; 120: 209-219.
14. McNamara JR, Small DM, Li Z, Schaefer EJ. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apoprotein B. J Lipid Res 1996; 37: 1924-1935.
15. Ziegler O, Mejean L, Igau B, Fruchart JC, Drouin P, Fievet C. Accessibility of human apolipoprotein B-100 epitopes in insulin-dependent diabetes: relation with the surface lipid environment of atherogenic particles. Diabetes Metab 1996; 22: 179-184.
16. Tomkin GH, Owens D. Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 2001; 17: 27-43.
17. Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G, Bonaduce D, Condorelli M, Reaven PD, Napoli C. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 2001; 22: 2045-2047.
18. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, Wong H, Peters AL. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312-320.
19. Császár A, Dieplinger H, Sandholzer C, Karadi I, Juhasz E, Drexel H, Halmos T, Romics L, Patsch JR, Utermann G. Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia 1993; 36: 47-51.
20. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD. Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM: results from follow-up in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 1218-1226.
21. Ulloa N, Bustos P, Castro G, Fruchart J, Vera M, Fruchart JC, Calvo C. Characterization of monoclonal antibodies against apolipoproteins A-I and A-II. Epitope expression into LpAI and LpAI:AII particles. Hybridoma 1999; 18: 513-520.
22. Bustos P, Ulloa N, Calvo C, Muller D, Duran D, Martinez J, Salazar L, Quiroga A. Monoclonal antibodies to human apolipoproteins A-I and A-II: application to the study of HDL subpopulations. Clin Chim Acta 2000; 299: 151-167.
23. Bustos P, Calvo C, Ulloa N, Quiroga A, Sepulveda J. An immunoenzymatic procedure for human apo B-containing particles quantification using monoclonal antibodies. Hybridoma 1998; 17: 395-401.
24. Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996; 45: 1267-1272.
25. Idzior-Walus B, Mattock MB, Solnica B, Stevens L, Fuller JH. Factors associated with plasma lipids and lipoproteins in type 1 diabetes mellitus. Diabet Med 2001; 18: 786-796.
26. Chaturvedi N, Fuller JH, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001; 24: 2071-2077.
27. Kahri J, Groop PH, Viberti G, Elliott T, Taskinen MR. Regulation of apolipoprotein A-I-containing lipoproteins in IDDM. Diabetes 1993; 42: 1281-1288.
28. Valabhji J, McColl AJ, Schachter M, Dhanjil S, Richmond W, Elkeles RS. High density lipoprotein composition and paraoxonase activity in type 1 diabetes. Clin Science 2001; 101: 659-670.
29. Puchois P, Kandoussi A, Fièvet P, Fourrier JL, Bertrand M, Koren E, Fruchart JC. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68: 35-40.
30. Calvo C, Olmos A, Ulloa N, Bustos A, Toledo L, Durán D, Naveas R. Lipoprotein particles LpA-I, LpA-I:A-II and LpB in coronary artery disease. Rev Med Chile 2000; 128: 9-16.
31. Blanco-Vaca F, Escolà-Gil JC, Martín-Campos JM, Julve J. Role of apo A-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 2001; 42: 1727-1739.
32. Castellani LW, Navab M, Van Lenten BJ, Hedrick CC, Hama SY, Goto AM, Fogelman AM, Lusis AJ. Over-expression of apoprotein A-II in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 1997; 100: 464-474.
33. Singh TP, Groehn H, Kazmers A. Vascular function and carotid intimal-medial thickness in children with insulin-dependent diabetes mellitus. J Am Coll Cardiol 2003; 41: 661-665.
34. Ohta T, Nishiyama S, Nakamura T, Saku K, Maung KK, Matsuda I. Predominance of low density lipoprotein particles and lower fractional esterification rate of cholesterol in high density lipoprotein in children with insulin-dependent diabetes mellitus. Eur J Pediatr 1998; 157: 276-281.
35. Colhoun HM, Otvos JD, Rubens MB, Taskinen M-R, Underwood SR, Fuller JH. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes 2002; 51: 1949-1956.
36. Sibley SD, Hokanson JE, Steffes MW, Purnell JQ, Marcovina SM, Cleary PA, Brunzell JD. Increased small dense LDL and intermediate density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 1999; 22: 1165-1170.
37. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000; 28: 1708-1716.
38. Calvo C, Verdugo C. Association in vivo of glycated apolipoprotein A-I with high density lipoproteins. Eur J Clin Chem Clin Biochem 1992; 30: 3-5.
39. Semenkovich CF, Heinecke JW. The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 1997; 46: 327-334.
40. Ferretti G, Rabini RA, Bacchetti T, Vignini A, Salvolini E, Ravaglia F, Curatola G, Mazzanti L. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 2002; 87: 2180-2184.
41. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 46: S19-S24.
42. Akanji AO, Abdella N, Mojiminiyi OA. Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait. Clin Chim Acta 2002; 317: 171-176.
43. Ferrer I, Llopart R, Moyano D. Lipoprotein (a): its concentration in children with insulin-dependent diabetes mellitus. Med Clin 1995; 104: 565-567.
44. Wollesen F, Dahlen G, Berglund L, Berne C. Peripheral atherosclerosis and serum lipoprotein (a) in diabetes. Diabetes Care 1999; 22: 93-98.